Partners with industry leader DiaCarta to distribute QuantiVirus™ SARS-CoV-2 Test Kit;
In Canada and Mexico
Vancouver, BC – January 19, 2021 – Maitri Health Technologies Corp. (“Maitri”) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced it has signed a distribution agreement to offer a highly sensitive and accurate COVID-19 polymerase chain reaction (“PCR”) test as part of its comprehensive offering of personal protective equipment (“PPE”) and technology.
Maitri has partnered with DiaCarta, Inc. (“DiaCarta”), a California -based precision molecular diagnostics company with a global reputation in genomics and oncology testing. DiaCarta leveraged its diagnostic expertise to develop QuantiVirus, now certified in multiple countries and continents around the world.
In a recent report on US FDA, EUA approved tests the DiaCarta PCR test kits were ranked among the most effective (1) . “The high quality and sensitivity of the DiaCarta’s PCR test kits, which are verified by third-party clinical evaluations, is what attracted us to them,” said Andrew Morton , CEO. “Companies and healthcare officials can better protect their employees and communities if they have timely, accurate visibility about who has COVID-19 virus. The QuantiVirus test kits are easy to administer and the results are available in hours, not days, with commonly available lab equipment. We’ve come to learn that testing is critical for businesses and communities to help keep their people safer and healthier.”
Maitri’s partnership with DiaCarta includes an international distribution agreement, currently in Mexico and Canada . With US FDA, EUA and Mexican Cofepris authorizations in place, DiaCarta is currently under evaluation with Health Canada for approval.
The COVID-19 PCR test kits join Maitri’s extensive suite of PPE. 3D masks, patent-pending face shields, sanitizers and disinfectants – all integrated and supported by technology for improved tracking and tracing – help provide safer, more protected workplaces and communities.
|
(1) |
GenomeWeb, “FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results”, https://www.genomeweb.com/pcr/fda-publishes-first-batch-sars-cov-2-mdx-limit-detection-comparison-results#.YAZ40-hKhPY |
About Maitri Health Technologies
Maitri Health Technologies Corp. (CSE: MTEC, FRA: D84) is a global platform for healthcare supply security. Our mission is to enhance safety and quality of life, and keep organizations and economies running. Maitri provides a reliable source of innovative, certified personal protective equipment and testing solutions through an onshore manufacturing model. Our stable, scalable supply chain is integrated with unique digital technology to deliver a comprehensive healthcare supply platform. For more information: https://maitrihealth.ca/
For more information: investors@maitrihealth.ca
Forward-Looking Statements
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE Maitri Health Technologies Corp.
